Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
16M
-
Shares change
-
-1.51M
-
Total reported value, excl. options
-
$35M
-
Value change
-
-$11.2M
-
Number of buys
-
26
-
Number of sells
-
-28
-
Price
-
$2.19
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q1 2020
59 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q1 2020.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16M shares
of 120M outstanding shares and own 13.29% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (11.5M shares), VANGUARD GROUP INC (627K shares), DG Capital Management, LLC (546K shares), Bracebridge Capital, LLC (429K shares), JPMORGAN CHASE & CO (414K shares), Eversept Partners, LP (300K shares), RENAISSANCE TECHNOLOGIES LLC (294K shares), MILLENNIUM MANAGEMENT LLC (237K shares), D. E. Shaw & Co., Inc. (214K shares), and BlackRock Inc. (211K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.